Boehringer Ingelheim (Switzerland)

Recent papers from Boehringer Ingelheim (Switzerland)

1. Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD‐ONPediatric Pulmonology · 2026
2. Method evaluation of liquid biopsy proteomics for limited plasma volumeMolecular & Cellular Proteomics · 2026
3. C103-10 Prognostic Value of Circulating IL-11 in Patients With Progressive Pulmonary Fibrosis (INBUILD Trial)American Journal of Respiratory and Critical Care Medicine · 2026
4. A phase 1b study to evaluate the safety, tolerability and preliminary efficacy of a heterologous prime boost vaccination (ATP150/ATP152/ATP162, VSV-GP154) and ezabenlimab (BI 754091) in patients with pancreatic ductal adenocarcinoma.Journal of Clinical Oncology · 2026
5. Population Pharmacokinetics and Exposure‐Response Model‐Based Bayesian Extrapolation of FVC ‐Based Efficacy Endpoints From Adults to Pediatric Patients Receiving NintedanibCPT Pharmacometrics & Systems Pharmacology · 2025
6. The Second Mitochondria‐Derived Activator of Caspases Mimetic BI 891065 in Patients With Advanced Solid Tumors: Results From Two Phase I StudiesCancer Medicine · 2025
7. A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese menExpert Opinion on Investigational Drugs · 2025
8. Report of the AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Japan Pharmaceutical Manufacturers Association: an overview of recent publications about AI pathologyJournal of Toxicologic Pathology · 2025
9. Assessments of life cycle and biodegradation properties uncovered distinct profiles of pharmaceutical excipients guiding selection for drug formulationsGreen Chemistry · 2025
10. Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approachPediatric Pulmonology · 2024
11. Neuroimaging Biomarkers for Drug Discovery and Development in SchizophreniaBiological Psychiatry · 2024
12. Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical IndustryClinical Pharmacology & Therapeutics · 2023
13. Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human IntestineDrug Metabolism and Disposition · 2023
14. Development and Validation of a Proteomic Correlation Profiling Technique to Detect and Identify Enzymes Involved in Metabolism of Drugs of ConcernDrug Metabolism and Disposition · 2023
15. Impact of Direction of Transport on the Evaluation of Substrate Recognition of Mouse Multidrug and Toxin Extrusion Protein 1Drug Metabolism and Disposition · 2023
16. Impact of P-glycoprotein on intracellular drug concentration in peripheral blood mononuclear cells and K562 cellsDrug Metabolism and Pharmacokinetics · 2022
17. A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and PertuzumabJCO Precision Oncology · 2022
18. Effectiveness of an Educational Intervention on Inhaler Technique Proficiency in Chronic Obstructive Pulmonary Disease: A Single-Center Quality Improvement StudyJournal of Respiration · 2022
19. Nintedanib in children and adolescents with fibrosing interstitial lung diseasesEuropean Respiratory Journal · 2022
20. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ONAnnals of the Rheumatic Diseases · 2022